Key result
IV cangrelor during acute ischemic stroke intervention demonstrated a symptomatic intracranial hemorrhage rate of 6.2% and an intraprocedural thromboembolic complication rate of 0.8%.
Why the study?
Emergent stenting during acute ischemic stroke procedures requires immediate platelet inhibition, but data on IV cangrelor specifically in ischemic stroke interventions needed synthesis.
Does intravenous cangrelor safely prevent thromboembolic complications without excessive bleeding in patients undergoing acute ischemic stroke interventions with stenting?
Population
129 patients receiving IV cangrelor during acute ischemic stroke intervention
Authors
Loading...
Supports cangrelor as a low-bleeding antiplatelet option in acute stroke stenting; extends observational data but leaves open randomized confirmation.
Meta-Analysis (n=129)
Yes
Does intravenous cangrelor safely prevent thromboembolic complications without excessive bleeding in patients undergoing acute ischemic stroke interventions with stenting?
Intravenous cangrelor appears to be a safe antiplatelet option during acute ischemic stroke interventions requiring stenting, demonstrating a low rate of symptomatic intracranial hemorrhage and intraprocedural thromboembolic complications.
Paúl et al. (2021) conducted a meta-analysis in Acute ischemic stroke requiring intervention (n=129). IV cangrelor was evaluated on Incidence of symptomatic intracranial hemorrhage (SICH). IV cangrelor during acute ischemic stroke intervention demonstrated a symptomatic intracranial hemorrhage rate of 6.2% and an intraprocedural thromboembolic complication rate of 0.8%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: